Details of the Drug Combination

General Information of Drug Combination (ID: DCC8W8G)

Drug Combination Name
Elacestrant ONAPRISTONE
Indication
Disease Entry Status REF
Breast Cancer Phase 1 [1]
Component Drugs Elacestrant   DM8RLJ5 ONAPRISTONE   DMT6E5N
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Elacestrant
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Elacestrant Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Indication(s) of ONAPRISTONE
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [3]
ONAPRISTONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Progesterone receptor (PGR) TTUV8G9 PRGR_HUMAN Modulator [5]
------------------------------------------------------------------------------------
ONAPRISTONE Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
ONAPRISTONE Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Affects Binding [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05618613) Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
2 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217639.
3 Clinical pipeline report, company report or official report of Context Therapeutics.
4 RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56.
5 Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999 Feb;35(2):214-8.
6 Drug-metabolizing enzymes and transporters: expression in the human prostate and roles in prostate drug disposition. J Androl. 2006 Mar-Apr;27(2):138-50.
7 Ligand-selective targeting of the glucocorticoid receptor to nuclear subdomains is associated with decreased receptor mobility. Mol Endocrinol. 2005 Jun;19(6):1501-15. doi: 10.1210/me.2005-0050. Epub 2005 Feb 10.